about
CDC50A plays a key role in the uptake of the anticancer drug perifosine in human carcinoma cellsDiscovery of potent pteridine reductase inhibitors to guide antiparasite drug developmentLeishmania donovani develops resistance to drug combinationsFitness of Leishmania donovani parasites resistant to drug combinationsFunctional expression of a multidrug P-glycoprotein transporter of Leishmania.Bis-pyranobenzoquinones as a new family of reversal agents of the multidrug resistance phenotype mediated by P-glycoprotein in mammalian cells and the protozoan parasite Leishmania.Disruption of the lipid-transporting LdMT-LdRos3 complex in Leishmania donovani affects membrane lipid asymmetry but not host cell invasionLeishmania LABCG1 and LABCG2 transporters are involved in virulence and oxidative stress: functional linkage with autophagy.High-affinity binding of silybin derivatives to the nucleotide-binding domain of a Leishmania tropica P-glycoprotein-like transporter and chemosensitization of a multidrug-resistant parasite to daunomycin.Antileishmanial and antitrypanosomal activities of the 8-aminoquinoline tafenoquine.Reversion of human Pgp-dependent multidrug resistance by new sesquiterpenes from Zinowiewia costaricensis.ABC transporters in the protozoan parasite Leishmania.LABCG2, a new ABC transporter implicated in phosphatidylserine exposure, is involved in the infectivity and pathogenicity of LeishmaniaCombination of suboptimal doses of inhibitors targeting different domains of LtrMDR1 efficiently overcomes resistance of Leishmania spp. to Miltefosine by inhibiting drug effluxHigh-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease.Optimization by Molecular Fine Tuning of Dihydro-β-agarofuran Sesquiterpenoids as Reversers of P-Glycoprotein-Mediated Multidrug Resistance.Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes.Tyrosol and hydroxytyrosol derivatives as antitrypanosomal and antileishmanial agents.The Oral Antimalarial Drug Tafenoquine Shows Activity against Trypanosoma brucei.Dihydro-beta-agarofuran sesquiterpenes: a new class of reversal agents of the multidrug resistance phenotype mediated by P-glycoprotein in the protozoan parasite Leishmania.Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use.All in one: Leishmania major STT3 proteins substitute for the whole oligosaccharyltransferase complex in Saccharomyces cerevisiaeA new ABC half-transporter in Leishmania major is involved in resistance to antimony.The 8-aminoquinoline analogue sitamaquine causes oxidative stress in Leishmania donovani promastigotes by targeting succinate dehydrogenase.Trypanosoma cruzi: sequence of the ATP-binding site of a P-glycoprotein gene.The overexpression of an intracellular ABCA-like transporter alters phospholipid trafficking in Leishmania.Novel 1,2-dihydroquinazolin-2-ones: Design, synthesis, and biological evaluation against Trypanosoma brucei.Arylthiosemicarbazones as antileishmanial agents.Experimental resistance to drug combinations in Leishmania donovani: metabolic and phenotypic adaptations.Mechanisms of action of substituted β-amino alkanols on Leishmania donovani.Design, synthesis and anti-leishmanial activity of novel symmetrical bispyridinium cyclophanes.4-amino bis-pyridinium derivatives as novel antileishmanial agents.Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine).Alkyl-lysophospholipid resistance in multidrug-resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulatorOvercoming human P-glycoprotein-dependent multidrug resistance with novel dihydro-β-agarofuran sesquiterpenes.A new ATP-binding cassette protein is involved in intracellular haem trafficking in Leishmania.Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug.The LABCG2 Transporter from the Protozoan Parasite Leishmania Is Involved in Antimony Resistance.The anti-tumor alkylphospholipid perifosine is internalized by an ATP-dependent translocase activity across the plasma membrane of human KB carcinoma cells.
P50
Q24315876-52154A26-9B64-4672-ABFD-1FBB36728EF7Q27649767-5CC89643-D4C2-44D8-A2EC-E6FC77FB6C7DQ28484463-D63E9572-1A28-46AC-88CD-BD4602DEAE3EQ28545794-962D1A64-6484-40E3-91CB-D4ABC212FE1CQ33212375-CF9FC211-FE26-45E2-9AF3-F21B5F28FB54Q33379669-2A9327C9-AB67-484B-86DD-29C847E21FCDQ33701743-F205E7D3-06A2-41D6-869F-48B63E54F9C7Q33742497-BD715808-3DD3-4136-A02B-31BCF067CD05Q33981351-D390A1F4-D176-4619-AFAD-FD37B7FA8AEAQ34309401-1F19A191-9EE0-49CF-AE06-2E7710BA9E81Q34428504-4E8D2470-0D45-454B-AA31-68D24776062AQ34512513-5F0FCF5D-0F6B-478A-9082-2FF90DF19976Q34702464-0008C8A7-33DE-4746-B252-8E61662F01DAQ35023368-069C4BF2-03FA-44DA-81B7-570CEA3B7F56Q35353325-ADD5E205-D96A-4A95-B1EF-274D93A2C388Q35912067-465E1343-3D4F-479D-BF0F-D51F95FBEC53Q36001763-3ACB6EED-C500-444B-A194-B9E00856A54AQ36011483-2D96F856-FBA6-4714-8D46-F75657B4A1BEQ36076081-08BFC108-4227-4ADD-91C7-692F952B9081Q36264597-B445A14E-94A4-48F7-8812-5955C22DFFC6Q36524693-73201AAF-7EAA-4C9D-AF5A-113926E96B3CQ36854970-0971BFE8-EAC3-48D4-9084-C47C582C0B2BQ37036630-9C3E3D29-ABE6-4536-A957-BE60258F5632Q38283327-89EEAC5F-57B9-45E8-95C7-B9CF9928AAE8Q38305918-F79A1151-CFA1-435F-AAFD-D4DEAF2E7C21Q38329011-3540E547-372E-4305-8581-6B680F81C60BQ38669388-99890DF0-5F14-4700-9974-84583583409BQ38754662-C30D1B77-7AF1-4365-BD6B-B100E41BCCFCQ38904942-0D714625-2FE5-422B-BE58-BC24B9FC2056Q38930809-4823FAD7-7F27-49BD-B39F-022E440BC540Q38933388-C91DC624-4C4D-4C09-966F-87F6281FB410Q38998325-0C0F0391-5141-4E0C-8D97-5677DA9EB113Q39444298-FBD1E16E-B0F8-4618-8323-FCC41B5D97A4Q39444314-18286DC1-11DF-4965-B7C1-62D4A87A876CQ39478185-D1D210B9-B2CD-45C1-A09A-AA293D6004FEQ39487610-84127433-A173-4662-B64F-73875A7EA75DQ39604692-0BB7491F-F063-45CF-9380-7E311ABDBC7CQ39792515-F3DBF685-87E8-4157-A77E-D63AA6334034Q39883894-441C72A3-D73D-46FE-B1CB-9A9E8FF6D709Q40051289-EC8306AE-5256-4992-B42D-621587044F87
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Francisco Gamarro
@ast
Francisco Gamarro
@en
Francisco Gamarro
@es
Francisco Gamarro
@nl
type
label
Francisco Gamarro
@ast
Francisco Gamarro
@en
Francisco Gamarro
@es
Francisco Gamarro
@nl
prefLabel
Francisco Gamarro
@ast
Francisco Gamarro
@en
Francisco Gamarro
@es
Francisco Gamarro
@nl
P106
P21
P31
P496
0000-0003-1347-3440